$52.2 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$441.00 - $664.64The lowest and highst price in the last 52 weeks.
14.86xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$52.2 Billion|
|Enterprise Value||$51.3 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-9.9%|
|Outstanding Shares||105 Million|
|Avg 30 Day Volume||827 Thousand|
|Earnings per Share||$30.52|
|Price to Sales Ratio||6.36|
|Price to Book Ratio||4.78|
|Revenue to Enterprise Value||6.13|
|EBIT to Enterprise Value||17.58|
|Total Debt to Enterprise Value||0.05|
|Debt to Equity||0.24|
|Gross Profit||$7.9 Billion|
|Net Income||$3.46 Billion|
|Quarterly Earnings Growth (YoY)||+45.1%|
|Return on Equity||31.41%|
|Return on Assets||20.18%|
|Return on Invested Capital||20.18%|
Looking Into Regeneron Pharmaceuticals's Return On Capital Employed Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. …Benzinga, 5 days ago
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for treatment of COVID-19. Cipla will part...Benzinga, 6 days ago
Novartis AG (NYSE: NVS ) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to on...Benzinga, 8 days ago